Chymotrypsin >5.4 µKatal/mg Trypsin <1% Source : Bovine pancreas

Added to your cart

Chymotrypsin >5.4 µKatal/mg Trypsin <1% Source : Bovine pancreas

Cart subtotal: £0.00

View cart (0) Checkout

#SKU 031110C10

Get in touch to purchase this product

Contact our team of experts to discuss your requirements

Contact our expert team

Product Details

The chymotrypsins, of which there are several, are serine proteasesderived from the inactive precursor Chymotrypsinogen-A (Alpha–Chymotrypsinogen) and B, which are present in the pancreas and pancreatic juice. Chymotrypsinogen-A is activated by Trypsin, and depending on the method of activation, the principle chymotrypsins may be obtained. These are referred to as Alpha, beta, gamma, delta and pi chymotrypsins.Chymotrypsin specificity: hydrolysis of peptide bonds formed by hydrophobic amino acid residues such as Tyrosine, Phenylalanine and Tryptophan. It hydrolases tyrosyl, tryptophanyl, phenylalanyl peptides, amides and esters. Slow hydrolysis also occurs with aspartate, glutamine, histidine, leucine, lysine, methionine, serine and threonine..


More information



  • Abbreviations
  • Chymo, CTG
  • Associated Activity
  • Identification A : Purple/Red Identification B: No ColourpH in deionised H2O (10 mg/ml) : 3.0 – 5.0Absorbance @281nm :18.5 – 22.5Absorbance @250nm : ≤ 8Opalescence: ≤Soln IIMoisture: ≤5%
  • Lead Time
  • 14 weeks to 6 months raw material depending
  • Storage
  • Storage Temperature: -20oCStorage in Transit: ≤8
  • Shelf Life
  • Retest date 36 months
  • Source
  • Bovine pancreas
  • Activity
  • ≥5.4 μkatal/mg
  • EC Number
  • Unit Definition
  • The amount of enzyme causing an increase in extinction at 260nm of 0.001 per minute at 25°C and pH 5.0
  • Form
  • White or almost white, crystalline or amorphous powder, hygroscopic if amorphous.

Technical Documents

Product Specification (132.79KB)

Product Information (355.53KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands


The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.


Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.


Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox